Cardiometabolic benefits of glucagon-like peptide-1 receptor agonists and dual agonists: from obesity and diabetes to heart failure with preserved ejection fraction.
INTRODUCTION Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalisations and is increasing in prevalence, largely driven by obesity and Type 2 Diabetes Mellitus (T2DM). Glucagon-like-peptide receptor agonists (GLP-1 RAs) and the dual GLP-1/GIP agonist, tirzepatide...